Xuefeng Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xuefeng Zhao has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Qianming Chen
Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Engineering Research Center of Oral Biomaterials and Devices of Zhejiang Province , Hangzhou 310000
5 shared publications- Hang Zhao
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Research Unit of Oral Carcinogenesis and Management, West China Hospital of Stomatology, Chinese Academy of Medical Sciences, Sichuan University, Chengdu, China
4 shared publications - Qianming Chen
Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Hangzhou, China
4 shared publications Zhongyu Liu
State Key Laboratory of Oral Diseases and National Center for Stomatology and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University , Chengdu 610041
4 shared publicationsDing Bai
State Key Laboratory of Oral Diseases and National Center for Stomatology and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University , Chengdu 610041
3 shared publicationsLu Xing
State Key Laboratory of Oral Diseases and National Center for Stomatology and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University , Chengdu 610041
3 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Injectable matrix metalloproteinase-responsive nanoparticle hydrogel scaffold for sustained local drug delivery in fibrous dysplasia
RANKL inhibition has shown significant therapeutic benefit in fibrous dysplasia (FD). However, sustained RANKL inhibition is required to maintain its therapeutic effect. Moreover, disease rebound following discontinuation of denosumab, a human monoclonal RANKL antibody, poses a major clinical challenge to FD treatment, thereby highlighting the need for strategies that preserve lesion-level efficacy while limiting systemic exposure. Matrix metalloproteinases (MMPs), which are essential for osteoclast function and bone remodeling, have emerged as a key pathogenic pathway in FD. Lesion profiling revealed elevated expression of MMP-9, -13, and -14 in osteoclast-rich FD lesions, with dynamic regulation in response to pharmacologic RANKL inhibition and withdrawal. We hypothesized that MMPs may serve as lesion-associated biological cues for localized drug delivery in FD. We developed an injectable, sustained, and MMP-responsive local drug delivery system by integrating triglycerol monostearate nanoparticles within a dynamically crosslinked hyaluronic acid-based hydrogel scaffold (HPD/TGMS). To validate this strategy, the small-molecule RANKL inhibitor AS2676293 was loaded into TGMS to generate HPD/TGMS@A. Matrix metalloproteinase-mediated cleavage of the ester linkage in TGMS enabled protease-responsive drug release, further regulated by hydrogel-constrained perilesional retention. HPD/TGMS@A demonstrated favorable injectability, self-healing behavior, cytocompatibility, and MMP-dependent anti-osteoclastic activity in vitro. HPD/TGMS@A significantly attenuated FD lesion progression and improved bone microarchitecture in a GNASR201C knock-in FD mouse model through perilesional injection. Altogether, these findings establish HPD/TGMS as a localized, lesion-responsive drug delivery strategy in FD.
- 28 May 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Open AccessInjectable matrix metalloproteinase-responsive nanoparticle hydrogel scaffold for sustained local drug delivery in fibrous dysplasia
RANKL inhibition has shown significant therapeutic benefit in fibrous dysplasia (FD). However, sustained RANKL inhibition is required to maintain its therapeutic effect. Moreover, disease rebound following discontinuation of denosumab, a human monoclonal RANKL antibody, poses a major clinical challenge to FD treatment, thereby highlighting the need for strategies that preserve lesion-level efficacy while limiting systemic exposure. Matrix metalloproteinases (MMPs), which are essential for osteoclast function and bone remodeling, have emerged as a key pathogenic pathway in FD. Lesion profiling revealed elevated expression of MMP-9, -13, and -14 in osteoclast-rich FD lesions, with dynamic regulation in response to pharmacologic RANKL inhibition and withdrawal. We hypothesized that MMPs may serve as lesion-associated biological cues for localized drug delivery in FD. We developed an injectable, sustained, and MMP-responsive local drug delivery system by integrating triglycerol monostearate nanoparticles within a dynamically crosslinked hyaluronic acid-based hydrogel scaffold (HPD/TGMS). To validate this strategy, the small-molecule RANKL inhibitor AS2676293 was loaded into TGMS to generate HPD/TGMS@A. Matrix metalloproteinase-mediated cleavage of the ester linkage in TGMS enabled protease-responsive drug release, further regulated by hydrogel-constrained perilesional retention. HPD/TGMS@A demonstrated favorable injectability, self-healing behavior, cytocompatibility, and MMP-dependent anti-osteoclastic activity in vitro. HPD/TGMS@A significantly attenuated FD lesion progression and improved bone microarchitecture in a GNASR201C knock-in FD mouse model through perilesional injection. Altogether, these findings establish HPD/TGMS as a localized, lesion-responsive drug delivery strategy in FD.
- Open Access
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Protein kinase A is a dependent factor and therapeutic target in mouse models of fibrous dysplasia
Fibrous dysplasia is a skeletal disorder caused by activating mutations in Gαs, leading to bone fractures, deformities, and pain. Protein kinase A (PKA), the principal effector of Gαs, plays critical roles in various biological processes. However, its role in fibrous dysplasia is unknown. Here we demonstrate that PKA activation replicates fibrous dysplasia-like lesions in a transgenic mouse model expressing an activating mutation of PKA in the skeletal stem cell lineage. Mechanistically, PKA promotes osteoclastogenesis and aberrant osteogenic differentiation and proliferation of skeletal stem cells, while impairing mineralization. Downregulating PKA activity, using either a genetically engineered PKA inhibitor peptide or small-molecule inhibitors, effectively alleviates fibrous dysplasia lesions in a fibrous dysplasia mouse model and safeguards bone structure by increasing trabecular bone volume in a PKA-inhibition mouse model. Although long-term pharmacological PKA inhibition remains untested, these findings demonstrate that PKA is a dependent factor in fibrous dysplasia initiation and progression, underscoring its potential as a therapeutic target.
- 1 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Open AccessProtein kinase A is a dependent factor and therapeutic target in mouse models of fibrous dysplasia
Fibrous dysplasia is a skeletal disorder caused by activating mutations in Gαs, leading to bone fractures, deformities, and pain. Protein kinase A (PKA), the principal effector of Gαs, plays critical roles in various biological processes. However, its role in fibrous dysplasia is unknown. Here we demonstrate that PKA activation replicates fibrous dysplasia-like lesions in a transgenic mouse model expressing an activating mutation of PKA in the skeletal stem cell lineage. Mechanistically, PKA promotes osteoclastogenesis and aberrant osteogenic differentiation and proliferation of skeletal stem cells, while impairing mineralization. Downregulating PKA activity, using either a genetically engineered PKA inhibitor peptide or small-molecule inhibitors, effectively alleviates fibrous dysplasia lesions in a fibrous dysplasia mouse model and safeguards bone structure by increasing trabecular bone volume in a PKA-inhibition mouse model. Although long-term pharmacological PKA inhibition remains untested, these findings demonstrate that PKA is a dependent factor in fibrous dysplasia initiation and progression, underscoring its potential as a therapeutic target.
- Open Access
- 5 December 2024
- Published by Springer Nature in Research Square
Protein Kinase A is a Dependent Factor and Therapeutic Target in Fibrous Dysplasia
Fibrous dysplasia (FD) is a skeletal disorder caused by activating mutations in Gαs, leading to bone fractures, deformities, and pain. Protein kinase A (PKA), the principal effector of Gαs/cAMP signaling, plays critical roles in various biological processes. However, its role in FD is unknown. Here, we demonstrate that PKA activation replicates FD-like lesions in a transgenic mouse model expressing an activating mutation of the PKA catalytic subunit α (PKAcαW197R) in the skeletal stem cell (SSC) lineage. Mechanistically, PKA promotes osteoclastogenesis and aberrant osteogenic differentiation and proliferation of SSCs, while impairing mineralization. Interestingly, downregulating PKA activity, using either a genetically engineered PKA inhibitor peptide or small-molecule inhibitors, effectively alleviates FD lesions in an FD mouse model and safeguards bone health by increasing trabecular bone volume in an osteoporosis mouse model. These findings demonstrate that PKA is a dependent factor in FD initiation and progression, underscoring its potential as a therapeutic target.
- 5 December 2024
- Published by Springer Nature in Research Square
Open AccessProtein Kinase A is a Dependent Factor and Therapeutic Target in Fibrous Dysplasia
Fibrous dysplasia (FD) is a skeletal disorder caused by activating mutations in Gαs, leading to bone fractures, deformities, and pain. Protein kinase A (PKA), the principal effector of Gαs/cAMP signaling, plays critical roles in various biological processes. However, its role in FD is unknown. Here, we demonstrate that PKA activation replicates FD-like lesions in a transgenic mouse model expressing an activating mutation of the PKA catalytic subunit α (PKAcαW197R) in the skeletal stem cell (SSC) lineage. Mechanistically, PKA promotes osteoclastogenesis and aberrant osteogenic differentiation and proliferation of SSCs, while impairing mineralization. Interestingly, downregulating PKA activity, using either a genetically engineered PKA inhibitor peptide or small-molecule inhibitors, effectively alleviates FD lesions in an FD mouse model and safeguards bone health by increasing trabecular bone volume in an osteoporosis mouse model. These findings demonstrate that PKA is a dependent factor in FD initiation and progression, underscoring its potential as a therapeutic target.
- Open Access
- 24 October 2024
- Published by Elsevier in American Journal of Orthodontics and Dentofacial Orthopedics
- Vol. 167 (2) , 144-153
Transverse dentoalveolar development in Chinese children and adolescents: A cross-sectional study using revised Andrews’ Element III analysis
- 24 October 2024
- Published by Elsevier in American Journal of Orthodontics and Dentofacial Orthopedics
- Vol. 167 (2) , 144-153
Open AccessTransverse dentoalveolar development in Chinese children and adolescents: A cross-sectional study using revised Andrews’ Element III analysis
- 1 December 2021
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 131, 112485
Mg-Fe layered double hydroxides modified titanium enhanced the adhesion of human gingival fibroblasts through regulation of local pH level
- 1 December 2021
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 131, 112485
Mg-Fe layered double hydroxides modified titanium enhanced the adhesion of human gingival fibroblasts through regulation of local pH level
- Open Access
- 27 April 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (28) , 15842-15852
Silver ions blocking crystallization of guanosine-based hydrogel for potential antimicrobial applications
Ag+ was introduced to block the crystallization of FGd forming long lifetime stability supramolecular hydrogel (>6 months), which displayed low toxicity for NOK-SI cell and good antibacterial activities.
- 27 April 2018
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 8 (28) , 15842-15852
Open AccessSilver ions blocking crystallization of guanosine-based hydrogel for potential antimicrobial applications
Ag+ was introduced to block the crystallization of FGd forming long lifetime stability supramolecular hydrogel (>6 months), which displayed low toxicity for NOK-SI cell and good antibacterial activities.
- Open Access
- 27 December 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (3) , E428-E437
Expression of an active Gαsmutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance
Significance: We generated a novel conditional inducible mouse model of fibrous dysplasia (FD) by expressing mutantGNASin skeletal stem cells (SSCs) in a temporally controlled and tissue-specific fashion. Typical FD bone lesions developed rapidly in mutant embryos and postnatal mice.GNASpromoted PKA activation and proliferation of SSCs along the osteogenic lineage but impaired their differentiation to mature osteoblasts and triggered increased osteoclastogenesis and bone resorption. FD lesions reverted on cessation ofGNASexpression. Thus,GNASmutation is sufficient and necessary for FD initiation and maintenance. This model provides a valuable opportunity to identify the molecular mechanism underlying FD progression and accelerate the development of more effective treatment options.
- 27 December 2017
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (3) , E428-E437
Open AccessExpression of an active Gαsmutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance
Significance: We generated a novel conditional inducible mouse model of fibrous dysplasia (FD) by expressing mutantGNASin skeletal stem cells (SSCs) in a temporally controlled and tissue-specific fashion. Typical FD bone lesions developed rapidly in mutant embryos and postnatal mice.GNASpromoted PKA activation and proliferation of SSCs along the osteogenic lineage but impaired their differentiation to mature osteoblasts and triggered increased osteoclastogenesis and bone resorption. FD lesions reverted on cessation ofGNASexpression. Thus,GNASmutation is sufficient and necessary for FD initiation and maintenance. This model provides a valuable opportunity to identify the molecular mechanism underlying FD progression and accelerate the development of more effective treatment options.
- 20 June 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (484)
Genetic evidence that β-arrestins are dispensable for the initiation of β 2 -adrenergic receptor signaling to ERK
Ligand activation of β 2 -adrenergic receptors induces the phosphorylation of the kinase ERK in a β-arrestin–independent manner.
- 20 June 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 10 (484)
Genetic evidence that β-arrestins are dispensable for the initiation of β 2 -adrenergic receptor signaling to ERK
Ligand activation of β 2 -adrenergic receptors induces the phosphorylation of the kinase ERK in a β-arrestin–independent manner.
- 19 April 2017
- Published by SPIE-Intl Soc Optical Eng
- Vol. 10171, 101710
Building environment assessment and energy consumption estimation using smart phones
In this paper, an APP for building indoor environment evaluation and energy consumption estimation based on Android platform is proposed and established. While using the APP, the smart phone built-in sensors are called for real-time monitoring of the building environmental information such as temperature, humidity and noise, etc. the built-in algorithm is developed to calculate the heat and power consumption, and questionnaires, grading and other methods are used to feed back to the space heating system. In addition, with the application of the technology of big data and cloud technology, the data collected by users will be uploaded to the cloud. After the statistics of the uploaded data, regional difference can be obtained, thus providing a more accurate basis for macro-control and research of energy, thermal comfort, greenhouse effect. © (2017) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
- 19 April 2017
- Published by SPIE-Intl Soc Optical Eng
- Vol. 10171, 101710
Building environment assessment and energy consumption estimation using smart phones
In this paper, an APP for building indoor environment evaluation and energy consumption estimation based on Android platform is proposed and established. While using the APP, the smart phone built-in sensors are called for real-time monitoring of the building environmental information such as temperature, humidity and noise, etc. the built-in algorithm is developed to calculate the heat and power consumption, and questionnaires, grading and other methods are used to feed back to the space heating system. In addition, with the application of the technology of big data and cloud technology, the data collected by users will be uploaded to the cloud. After the statistics of the uploaded data, regional difference can be obtained, thus providing a more accurate basis for macro-control and research of energy, thermal comfort, greenhouse effect. © (2017) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
- Open Access
- 14 January 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , srep19296
Cysteine Dioxygenase Type 1 Inhibits Osteogenesis by Regulating Wnt Signaling in Primary Mouse Bone Marrow Stromal Cells
Mesenchymal stem cells (MSCs) are multipotent cells, which can give rise to variety of cell types, including adipocytes and osteoblasts. Previously, we have shown that cysteine dioxygenase type 1 (Cdo1) promoted adipogenesis of primary mouse bone marrow stromal cells (BMSCs) and 3T3-L1 pre-adipocytes via interaction with Pparγ. However, the role of Cdo1 in osteogenesis remains unclear. Here, we demonstrated that expression of Cdo1 was elevated during osteoblastic differentiation of BMSCs in vitro. Interestingly, knockdown of Cdo1 by siRNA led to an increased expression of osteogenic related genes, elevated alkaline phosphatase (ALP) activity, and enhanced mineralization. Overexpression of Cdo1 in BMSCs inversely suppressed the osteogenesis. Furthermore, we found that overexpression of Cdo1 impaired Wnt signaling and restricted the Wnt3a induced expression of osteogenic transcriptional factors, such as Runx2 and Dlx5. Collectively, our findings indicate Cdo1 suppresses osteogenic differentiation of BMSCs, through a potential mechanism which involves in Wnt signaling reduction concomitantly.
- 14 January 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , srep19296
Open AccessCysteine Dioxygenase Type 1 Inhibits Osteogenesis by Regulating Wnt Signaling in Primary Mouse Bone Marrow Stromal Cells
Mesenchymal stem cells (MSCs) are multipotent cells, which can give rise to variety of cell types, including adipocytes and osteoblasts. Previously, we have shown that cysteine dioxygenase type 1 (Cdo1) promoted adipogenesis of primary mouse bone marrow stromal cells (BMSCs) and 3T3-L1 pre-adipocytes via interaction with Pparγ. However, the role of Cdo1 in osteogenesis remains unclear. Here, we demonstrated that expression of Cdo1 was elevated during osteoblastic differentiation of BMSCs in vitro. Interestingly, knockdown of Cdo1 by siRNA led to an increased expression of osteogenic related genes, elevated alkaline phosphatase (ALP) activity, and enhanced mineralization. Overexpression of Cdo1 in BMSCs inversely suppressed the osteogenesis. Furthermore, we found that overexpression of Cdo1 impaired Wnt signaling and restricted the Wnt3a induced expression of osteogenic transcriptional factors, such as Runx2 and Dlx5. Collectively, our findings indicate Cdo1 suppresses osteogenic differentiation of BMSCs, through a potential mechanism which involves in Wnt signaling reduction concomitantly.